2 days ago
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Addus Homecare (ADUS) and Cytokinetics (CYTK)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on QuidelOrtho (QDEL – Research Report), Addus Homecare (ADUS – Research Report) and Cytokinetics (CYTK – Research Report) with bullish sentiments.
Confident Investing Starts Here:
QuidelOrtho (QDEL)
In a report issued on June 5, Conor McNamara from RBC Capital maintained a Buy rating on QuidelOrtho, with a price target of $60.00. The company's shares closed last Monday at $30.21, close to its 52-week low of $29.74.
According to McNamara is ranked 0 out of 5 stars with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and SOPHiA GENETICS.
QuidelOrtho has an analyst consensus of Moderate Buy, with a price target consensus of $45.00, which is a 48.4% upside from current levels. In a report issued on June 5, Craig-Hallum also maintained a Buy rating on the stock with a $60.00 price target.
Addus Homecare (ADUS)
In a report released yesterday, Ryan Daniels from William Blair maintained a Buy rating on Addus Homecare. The company's shares closed last Monday at $116.56.
According to Daniels is a 4-star analyst with an average return of 8.4% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Pediatrix Medical Group, and Lifestance Health Group.
Addus Homecare has an analyst consensus of Strong Buy, with a price target consensus of $135.17, representing a 18.7% upside. In a report issued on June 1, Jefferies also maintained a Buy rating on the stock with a $160.00 price target.
Cytokinetics (CYTK)
In a report issued on June 5, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company's shares closed last Monday at $33.13.
According to Timashev is a 3-star analyst with an average return of 2.9% and a 42.7% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $75.21 average price target, a 128.3% upside from current levels. In a report issued on May 26, Stifel Nicolaus also maintained a Buy rating on the stock with a $87.00 price target.
